Atlas Trials

The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)

Clinical trial NCT02273713 · COMPLETED

Trial details

NCT number
NCT02273713
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Esophageal CancerToxicity
Start date
2014-10-01
Primary completion
2017-03-01
Enrollment
154

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.